Di Yi Cai Jing·2026-02-24 05:04Core Insights - 2026 is a critical year for Novo Nordisk as its semaglutide market share faces pressure from competitors led by Eli Lilly [1][2] - Novo Nordisk's new weight loss drug CagriSema showed a weight loss of 23% in a head-to-head trial against Eli Lilly's tirzepatide, which achieved 25.5% [1] - Following the disappointing trial results, Novo Nordisk's stock plummeted over 16%, erasing all gains since the launch of semaglutide [1][3] Company Developments - CEO Mike Doustdar aims to navigate the company through this "crisis" by pushing the new generation weight loss therapy to market [2] - Analysts indicate that CagriSema is crucial for Novo Nordisk's growth, with expectations that 60% of the company's future growth will come from this drug [2] Market Dynamics - CagriSema combines Cagrilintide and GLP-1 component semaglutide, administered weekly [3] - Since reaching its peak market value in 2024, Novo Nordisk has lost over $470 billion in market capitalization, erasing all gains from the launch of semaglutide [3] - Eli Lilly's stock surged following Novo Nordisk's weak clinical data, bringing its market value close to $1 trillion, with expectations for continued growth in tirzepatide demand [3]